Editing HBM Healthcare Investments
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.
Latest revision | Your text | ||
Line 180: | Line 180: | ||
It is worth noting that while the proportion of profitable companies in HBMN’s portfolio has jumped from 21% to 47% during the year, this represents the most advanced stage of development in any company’s product portfolio, and should not be taken to indicate a lack of innovation in the remaining holdings. Indeed, HBMN’s portfolio companies are expected to have a busy year of trial readouts (Phases I, II and III) and product approvals during the remainder of 2022. | It is worth noting that while the proportion of profitable companies in HBMN’s portfolio has jumped from 21% to 47% during the year, this represents the most advanced stage of development in any company’s product portfolio, and should not be taken to indicate a lack of innovation in the remaining holdings. Indeed, HBMN’s portfolio companies are expected to have a busy year of trial readouts (Phases I, II and III) and product approvals during the remainder of 2022. | ||
{| class="wikitable" | {| class="wikitable" | ||
|+Exhibit 7: Portfolio exposure by clinical development stage (% unless stated)<ref>Source: HBM Healthcare Investments, Edison Investment Research. Note: *Classified by most advanced development stage.</ref> | |+Exhibit 7: Portfolio exposure by clinical development stage* (% unless stated)<ref>Source: HBM Healthcare Investments, Edison Investment Research. Note: *Classified by most advanced development stage.</ref> | ||
! | ! | ||
!Portfolio end-March 2022 | !Portfolio end-March 2022 |